文献速递浆细胞疾病

多发性骨髓瘤及其前驱状态患者的影像学检查方法

How do we image patients with multiple myeloma and precursor states?
PubMed 文献 · Br J Haematol · 2023-05-22

本文综述了FDG PET/CT与全身弥散加权MRI(WB DW-MRI)在多发性骨髓瘤及其前驱状态中的应用,指出WB DW-MRI在基线肿瘤负荷检测和疗效评估方面较PET/CT更敏感,并已成为冒烟型骨髓瘤排除骨髓瘤定义事件的首选影像方法。文章通过3个临床案例展示了现代影像在管理中的使用方式,并基于IMWG共识指南发布后的新数据提供依据,同时指出需未来研究的知识空白。

要点

  • WB DW-MRI在检测基线肿瘤负荷和评估治疗后反应方面比PET/CT更敏感。
  • 冒烟型骨髓瘤中WB DW-MRI是排除两个及以上明确病灶的首选影像方法。
  • PET/CT和WB DW-MRI均可用于监测治疗反应,提供与IMWG反应评估和骨髓微小残留病互补的信息。

核心结论

  • WB DW-MRI在检测基线肿瘤负荷和评估治疗后反应方面较PET/CT更敏感。
  • 在冒烟型骨髓瘤中,WB DW-MRI现为排除两个及以上明确病灶(按更新IMWG标准视为骨髓瘤定义事件)的首选影像方法。
  • PET/CT和WB DW-MRI已成功用于监测治疗反应,并提供与IMWG反应评估和骨髓微小残留病互补的信息。

研究设计与样本

  • 本文为综述,依据前瞻性和回顾性研究数据,并展示3个临床案例说明多发性骨髓瘤及前驱状态患者的影像学管理方法。
  • 重点纳入IMWG影像共识指南发布后出现的最新数据。

主要发现

  • 前瞻性和回顾性研究均表明WB DW-MRI在检测基线肿瘤负荷和评估治疗后反应方面较PET/CT更敏感。
  • 在冒烟型骨髓瘤患者中,WB DW-MRI可排除两个及以上明确病灶,这些病灶按更新IMWG标准被视为骨髓瘤定义事件。
  • PET/CT和WB DW-MRI监测治疗反应的信息与IMWG反应评估及骨髓微小残留病互补。

关键数值与推荐

  • WB DW-MRI为冒烟型骨髓瘤排除两个及以上明确病灶(按更新IMWG标准视为骨髓瘤定义事件)的首选影像方法。
  • FDG PET/CT和WB DW-MRI是应用最广泛且标准化的两种功能影像模式。

临床怎么用

  • 原文通过3个案例展示作者在多发性骨髓瘤及前驱状态患者管理中如何使用现代影像,并基于前瞻性和回顾性研究数据提供依据。
  • 原文指出需未来研究的知识空白。

局限性

  • 原文指出需未来研究的知识空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in morphological and functional imaging have led to superior detection of early bone disease, bone marrow infiltration, paramedullary and extramedullary involvement in multiple myeloma. The two functional imaging modalities that are most widely used and standardized are 18F-fluorodeoxyglucose-Positron emission tomography/computed tomography (FDG PET/CT) and whole-body magnetic resonance imaging with diffusion-weighted imaging (WB DW-MRI). Both prospective and retrospective studies have demonstrated that WB DW-MRI is more sensitive than PET/CT in the detection of baseline tumour burden and to assess response after therapy. In patients with smouldering multiple myeloma, WB DW-MRI is now the preferred imaging modality to rule out two or more unequivocal lesions which would be considered a myeloma-defining event by the updated international myeloma working group (IMWG) criteria. In addition to sensitive detection of baseline tumour burden, both PET/CT and WB DW-MRI have been successfully used for monitoring response to therapy and provide information that is complementary to IMWG response assessment and bone marrow minimal residual disease. In this article, we present 3 vignettes illustrating how we approach the use of modern imaging in the management of patients with multiple myeloma and precursor states, with a specific focus on recent data that have emerged since the publication of the IMWG consensus guideline on imaging. We have utilized data from prospective and retrospective studies to provide a rationale for our approach to imaging in these clinical scenarios and highlighted knowledge gaps requiring future investigation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chakraborty R, Hillengass J, Lentzsch S, et al. How do we image patients with multiple myeloma and precursor states? Br J Haematol. 2023. PMID: 37217164. doi:10.1111/bjh.18880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。